| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2010.33.2585 |
| P698 | PubMed publication ID | 21555684 |
| P50 | author | Christian F Singer | Q91125264 |
| Christian Marth | Q17122650 | ||
| Michael Gnant | Q18025935 | ||
| P2093 | author name string | Georg Pfeiler | |
| Hellmut Samonigg | |||
| Richard Greil | |||
| Michael Seifert | |||
| Peter Dubsky | |||
| Brigitte Mlineritsch | |||
| Guenther G Steger | |||
| Susanne Taucher | |||
| Vesna Bjelic-Radisic | |||
| Herbert Stoeger | |||
| Sabine Pöstlberger | |||
| Robert Königsberg | |||
| Christian Fesl | |||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2653-2659 | |
| P577 | publication date | 2011-05-09 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial | |
| P478 | volume | 29 |
| Q36348871 | A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer |
| Q39260461 | Adjuvant Endocrine Therapy in Breast Cancer: Evolving Paradigms in Premenopausal Women. |
| Q91963162 | Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows |
| Q36976772 | Adjuvant endocrine therapy in premenopausal women with breast cancer |
| Q36457989 | Adjuvant hormonal therapy in premenopausal women with breast cancer |
| Q85262391 | Anastrozole and Fulvestrant in Metastatic Breast Cancer |
| Q34228066 | Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients. |
| Q84578701 | Aromatase Inhibition in Obese Women: How Much Is Enough? |
| Q36946008 | Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved |
| Q48374983 | Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels |
| Q83297097 | Aromatase inhibitors in premenopausal breast cancer |
| Q55090991 | Aromatase inhibitors in premenopausal women with breast cancer: the state of the art and future prospects. |
| Q96608943 | Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study |
| Q37632155 | Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole |
| Q36325915 | Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole? |
| Q35682481 | Cell-Based High-Throughput Screening for Aromatase Inhibitors in the Tox21 10K Library |
| Q38121736 | Clinical management of obese patients with cancer |
| Q38162118 | Clinical studies examining the impact of obesity on breast cancer risk and prognosis |
| Q54974390 | Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer? |
| Q26795751 | Current medical treatment of estrogen receptor-positive breast cancer |
| Q88963712 | Early breast cancer: why does obesity affect prognosis? |
| Q39143601 | Effect of body mass index on overall survival of patients with allogeneic hematopoietic stem cell transplantation |
| Q36419177 | Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index. |
| Q50954996 | Efficacy of combined therapy of goserelin and letrozole on very young women with advanced breast cancer as first-line endocrine therapy |
| Q36775349 | Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial |
| Q33352521 | Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle |
| Q36963393 | Hormonal therapies in young breast cancer patients: when, what and for how long? |
| Q46733261 | Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole |
| Q38853194 | Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials |
| Q36296120 | Impact of body mass index on breast cancer in accordance with the life-stage of women |
| Q37182285 | Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer |
| Q37180380 | Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity |
| Q55369032 | Increasing preoperative body size in breast cancer patients between 2002 and 2016: implications for prognosis. |
| Q38046167 | Lifestyle Factors in Cancer Survivorship |
| Q90013348 | Mammary adipose stromal cells derived from obese women reduce sensitivity to the aromatase inhibitor anastrazole in an organotypic breast model |
| Q41212362 | Memory and Spatial Cognition in Breast Cancer Patients Undergoing Adjuvant Endocrine Therapy |
| Q38026242 | Menopausal status and adjuvant hormonal therapy for breast cancer patients: A practical guideline |
| Q89761376 | Mitogen-Activated Protein Kinase (MAPK) and Obesity-Related Cancer |
| Q85795082 | Need for Estradiol Assays With a Lower Functional Sensitivity in Clinical Studies Examining Postmenopausal Women Treated With Aromatase Inhibitors |
| Q91000127 | Obesity and cancer treatment efficacy: Existing challenges and opportunities |
| Q36368902 | Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial |
| Q37690278 | Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis |
| Q47921924 | Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population. |
| Q61799036 | Obesity, Leptin and Breast Cancer: Epidemiological Evidence and Proposed Mechanisms |
| Q37200502 | Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients |
| Q38968531 | Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer. |
| Q39027934 | Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology. |
| Q30543788 | Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 |
| Q36426540 | Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project. |
| Q36075477 | Preoperative Underweight Patients with Upper Tract Urothelial Carcinoma Survive Less after Radical Nephroureterectomy |
| Q33680312 | Profound reduction of ovarian estrogen by aromatase inhibition in obese women |
| Q33739138 | Status of adjuvant endocrine therapy for breast cancer |
| Q84578681 | Suppression of Plasma Estrogen Levels by Letrozole and Anastrozole Is Related to Body Mass Index in Patients With Breast Cancer |
| Q52324116 | The Impact of Obesity on Breast Cancer |
| Q64111092 | The Impact of Obesity on Breast Cancer Diagnosis and Treatment |
| Q38510960 | The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer. |
| Q37579337 | The association between adiposity and breast cancer recurrence and survival: A review of the recent literature |
| Q53608272 | The effect of exercise on body composition and bone mineral density in breast cancer survivors taking aromatase inhibitors |
| Q38156366 | The obesity-inflammation-eicosanoid axis in breast cancer |
| Q37081862 | The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. |
| Q36491430 | The role of the bone microenvironment in skeletal metastasis. |
| Q36915182 | Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy |
| Q44683558 | What Is the Optimal Endocrine Therapy for Postmenopausal Women With Hormone Receptor–Positive Early Breast Cancer? |
| Q26797301 | Why does obesity promote cancer? Epidemiology, biology, and open questions |
Search more.